Navigating Barriers Which Inhibit Optimal Use of Bispecifics

EP: 1.Conditions for Administering Bispecific Therapy

Now Viewing

EP: 2.Navigating Barriers Which Inhibit Optimal Use of Bispecifics

EP: 3.Key Decision Makers and Contributors Involved In Bispecific Administration

EP: 4.Pain Points In Bispecific Operationalization

EP: 5.Risk Evaluation and Mitigation Strategies [REMS] Program Considerations For Bispecific Therapy

EP: 6.Optimizing Bispecific Use Through EMR Utilization

EP: 7.Best Practices For Uptake and Use of Bispecific Therapy

EP: 8.Achieving Seamless Care Transitions With Patients Receiving Bispecific Therapy

EP: 9.Intro to Bispecific Therapy: Implementation Essentials for Novice Institutions

EP: 10.Key Elements In Monitoring for Potential Adverse Events with Bispecific Antibodies

EP: 11.Protocol For Urgent and Around-the-Clock Bispecific Care

EP: 12.Obstacles to Optimal Transitions of Care Between Academic and Community Settings When Utilizing Bispecific Antibodies

EP: 13.Managed Care Considerations Within Bispecific Landscape

EP: 14.Payor-Provider Collaboration Driving Optimal Bispecific Therapy Strategies

EP: 15.Medication Assistance Programs Mitigating Financial Burden For Patients Receiving Bispecific Therapy

EP: 16.Bispecific Therapies: Current and Future Considerations

The following is a video synopsis/summary of a Peer Exchange involving Ryan Haumschild, PharmD, MS, MBA, CPEL; Kirollos Hanna, PharmD, BCPS, BCOP, FACCC; Sarah Rockwell, PharmD, BCOP; Melody Chang, RPh, MBA, BCOP; and Ryan Cain, PA-C.

The video discusses potential issues and opportunities with utilizing bispecific monoclonal antibodies in cancer care. Barriers exist in patient access and treatment center experience with these novel therapies. Patients in rural or suburban areas may lack proximity to academic or community centers familiar with bispecific administration protocols. The frequent dosing schedule also poses transportation challenges.

During treatment, infections requiring therapy holds or dose modifications add complexity. Restarting after holds requires decisions on re-initiation dosing and potential referral to academic centers. Grade 3 or 4 infections and hematologic adverse events are common during maintenance therapy. Sequencing bispecifics with other therapies like chimeric antigen receptor T-cell therapy also lacks clarity.

However, opportunities exist to overcome these barriers through clinical trials and coordination between academic and community providers to ensure appropriate outpatient delivery. Well-defined protocols can facilitate identification of hospitalization needs, preemptive medication dosing, patient monitoring, and triage lines. Designating organizational champions to oversee bispecific implementation across disease states can also streamline the process.

Video synopsis is AI-generated and reviewed by AJMC editorial staff.